Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone von Kiladjian, J-J, Giraudier, S, Cassinat, B

Volltext

The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders von Maslah, N, Cassinat, B, Verger, E, Kiladjian, J-J, Velazquez, L

Volltext

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Vannucchi, A.M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J.-J., Kröger, N., Thiele, J., Buske, C.

Volltext

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both von Koschmieder, S, Mughal, T I, Hasselbalch, H C, Barosi, G, Valent, P, Kiladjian, J-J, Jeryczynski, G, Gisslinger, H, Jutzi, J S, Pahl, H L, Hehlmann, R, Maria Vannucchi, A, Cervantes, F, Silver, R T, Barbui, T

Volltext

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis von Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T

Volltext

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms von Kiladjian, J-J, Chomienne, C, Fenaux, P

Volltext

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis von Vannucchi, Alessandro M, Kantarjian, Hagop M, Kiladjian, Jean-Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A, Sarlis, Nicholas J, Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan

Volltext

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes von KILADJIAN, J.-J, BOURGEOIS, E, LOBE, I, BRAUN, T, VISENTIN, G, BOURHIS, J.-H, FENAUX, P, CHOUAIB, S, CAIGNARD, A

Volltext

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis von Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, Vannucchi, A M

Volltext

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations von Marchetti, M, Barosi, G, Cervantes, F, Birgegård, G, Griesshammer, M, Harrison, C, Hehlmann, R, Kiladjian, J-J, Kröger, N, McMullin, M F, Passamonti, F, Vannucchi, A, Barbui, T

Volltext

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients von Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Volltext

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Workin... von Barosi, G, Tefferi, A, Besses, C, Birgegard, G, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, Barbui, T

Volltext

What are RBC-transfusion-dependence and -independence? von Gale, R.P, Barosi, G, Barbui, T, Cervantes, F, Dohner, K, Dupriez, B, Gupta, V, Harrison, C, Hoffman, R, Kiladjian, J.-J, Mesa, R, Mc Mullin, M.F, Passamonti, F, Ribrag, V, Roboz, G, Saglio, G, Vannucchi, A, Verstovsek, S

Volltext

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neopla... von Jovanovic, J V, Ivey, A, Vannucchi, A M, Lippert, E, Oppliger Leibundgut, E, Cassinat, B, Pallisgaard, N, Maroc, N, Hermouet, S, Nickless, G, Guglielmelli, P, van der Reijden, B A, Jansen, J H, Alpermann, T, Schnittger, S, Bench, A, Tobal, K, Wilkins, B, Cuthill, K, McLornan, D, Yeoman, K, Akiki, S, Bryon, J, Jeffries, S, Jones, A, Percy, M J, Schwemmers, S, Gruender, A, Kelley, T W, Reading, S, Pancrazzi, A, McMullin, M F, Pahl, H L, Cross, N C P, Harrison, C N, Prchal, J T, Chomienne, C, Kiladjian, J J, Barbui, T, Grimwade, D

Volltext

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition von Chaligné, R, Tonetti, C, Besancenot, R, Roy, L, Marty, C, Mossuz, P, Kiladjian, J-J, Socié, G, Bordessoule, D, Le Bousse-Kerdilès, M-C, Vainchenker, W, Giraudier, S

Volltext

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms von Berdeja, J., Palandri, F., Baer, M.R., Quick, D., Kiladjian, J.J., Martinelli, G., Verma, A., Hamid, O., Walgren, R., Pitou, C., Li, P.L., Gerds, A.T.

Volltext

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus von Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F.

Volltext

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis von Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T

Volltext

Is there consensus on consensus? von Kiladjian, J-J, Gale, R P

Volltext

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence von Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P

Volltext